PURPOSE: All current recommendations include calcium and vitamin D (Ca-D) as an integrated part of osteoporosis treatment. The purpose of this pilot study was to analyze compliance with a fixed combination of Ca-D in women persistent with the treatment. PATIENTS AND METHODS: An observational study was carried out in three osteocenters in the Czech Republic. Women with osteoporosis ≥55 years of age concurrently treated with oral ibandronate were eligible. Compliance was evaluated in a period of 3 months by Medication Event Monitoring System (MEMS), tablet count, and self-report. Nonpersistence was defined as a MEMS-based gap in the use of Ca-D to be 30 days or more. RESULTS: A total of 73 patients were monitored, of which 49 patients were analyzed (target population). Based on MEMS, mean overall compliance was 71%; good compliance (≥80%) was observed in 59% of the patients. As many as 71% of the patients took drug holidays (≥3 consecutive days without intake); overall compliance of these patients was 59% and was slightly lower on Fridays and weekends. Patients without drug holidays were fully compliant (did not omit individual doses). Compliance differed according to daily time at which the patients mostly used the Ca-D. Afternoon/evening takers showed a mean overall compliance of 82% while morning/night takers only 51% (P=0.049). Based on MEMS, tablet count, and self-report, compliance ≥75% was observed in 59%, 100%, and 87% of the patients, respectively. Outcomes obtained by the three methods were not associated with each other. Undesirable concurrent ingestion of Ca-D and ibandronate was present only twice. CONCLUSION: Despite almost perfect self-reported and tablet count-based compliance, MEMS-based compliance was relatively poor. Consecutive supplementation-free days were common; more than two-thirds of the patients took at least one drug holiday. This pilot study showed drug holiday to be the most important type of noncompliance with Ca-D in those who are persistent with the treatment.

Department of Social and Clinical Pharmacy Faculty of Pharmacy in Hradec Kralove Charles University Prague Hradec Kralove Czech Republic

Osteocentre Institute of Clinical Biochemistry and Diagnostics Charles University Prague Faculty of Medicine and University Hospital in Hradec Kralove Hradec Kralove Czech Republic

See more in PubMed

Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57. PubMed PMC

Strom O, Borgstrom F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos. 2011;6(1–2):59–155. PubMed

Tang BM, Eslick GD, Nowson GD, Smith C, Bensoussan A. Use of calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years or older: a meta-analysis. Lancet. 2007;370:657–666. PubMed

Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719. PubMed

Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–1031. PubMed

Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493–1501. PubMed

Bruyère O, Malaise O, Neuprez A, Collette J, Reginster JY. Prevalence of vitamin D inadequacy in European postmenopausal women. Curr Med Res Opin. 2007;23:1939–1944. PubMed

Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–581. PubMed

Brunner R, Dunbar-Jacob J, Leboff MS, et al. Predictors of adherence in the women’s health initiative calcium and vitamin D trial. Behav Med. 2009;34(4):145–155. PubMed PMC

Giusti A1, Barone A, Razzano M, et al. Persistence with calcium and vitamin D in elderly patients after hip fracture. J Bone Miner Metab. 2009;27(1):95–100. PubMed

Castelo-Branco C, Cortés X, Ferrer M. Treatment persistence and compliance with a combination of calcium and vitamin D. Climacteric. 2010;13(6):578–584. PubMed

Sanfelix-Genovés J, Gil-Guillén VF, Orozco-Beltran D, et al. Determinant factors of osteoporosis patients’ reported therapeutic adherence to calcium and/or vitamin D supplements: a cross-sectional, observational study of postmenopausal women. Drugs Aging. 2009;26(10):861–869. PubMed

Reymondier A, Caillet P, Abbas-Chorfa F, et al. MENOPOST – calcium and vitamin D supplementation in postmenopausal osteoporosis treatment: a descriptive cohort study. Osteoporos Int. 2013;24(2):559–566. PubMed

Díez A, Carbonell C, Calaf J, Caloto MT, Nocea G. Observational study of treatment compliance in women initiating antiresorptive therapy with or without calcium and vitamin D supplements in Spain. Menopause. 2012;19(1):89–95. PubMed

Vytrisalova M, Touskova T, Ladova K, et al. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter. Climacteric. 2015;18:1–9. PubMed

Shi L, Liu J, Fonseca V, Walker P, Kalsekar A, Pawaskar M. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes. 2010;8(1):99. PubMed PMC

Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care. 2001;10:42–45. PubMed

Schousboe JT, Dowd BE, Davison ML, Kane RL. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int. 2010;21:1899–1909. PubMed

Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23:223–231. PubMed

Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. PubMed PMC

Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–1117. PubMed PMC

Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. Vasc Health Risk Manag. 2007;3:235–242. PubMed PMC

Zeller A, Schroeder K, Peters TJ. An adherence self-report questionnaire facilitated the differentiation between nonadherence and nonresponse to antihypertensive treatment. J Clin Epidemiol. 2008;61(3):282–288. PubMed

Gillespie D, Hood K, Farewell D, Stenson R, Probert C, Hawthorne AB. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. Inflamm Bowel Dis. 2014;20(1):82–91. PubMed

Finigan J, Naylor K, Paggiosi MA, Peel NF, Eastell R. Adherence to raloxifene therapy: assessment methods and relationship with efficacy. Osteoporos Int. 2013;24(11):2879–2886. PubMed

Cals JW, Hopstaken RM, Le Doux PH, Driessen GA, Nelemans PJ, Dinant GJ. Dose timing and patient compliance with two antibiotic treatment regimens for lower respiratory tract infections in primary care. Int J Antimicrob Agents. 2008;31(6):531–536. PubMed

Osterberg L, Blasche T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. PubMed

Voils CI, Hoyle RH, Thorpe CT, Maciejewski ML, Yancy WS., Jr Improving the measurement of self-reported medication nonadherence. J Clin Epidemiol. 2011;64:250–254. PubMed PMC

Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics. 2010;28(12):1097–1107. PubMed

Hendrychova T, Vytrisalova M, Smahelova A, Vlcek J, Kubena AA. Adherence in adults with type 1 diabetes mellitus correlates with treatment satisfaction but not with adverse events. Patient Prefer Adherence. 2013;7:867–876. PubMed PMC

Vytrisalova M, Blazkova S, Palicka V, et al. Self-reported compliance with osteoporosis medication – qualitative aspects and correlates. Maturitas. 2008;60(3):223–229. PubMed

Ladova K, Matoulkova P, Zadak Z, et al. Self-reported adherence by MARS-CZ reflects LDL cholesterol goal achievement among statin users: validation study in the Czech Republic. J Eval Clin Pract. 2014;20(5):671–677. PubMed

McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67(3):267–277. PubMed PMC

Zeller A, Ramseier E, Teagtmeyer A, Battegay E. Patients’ self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertension Res. 2008;31(11):2037–2043. PubMed

Nieuwenhuis MM, Jaarsma T, van Veldhuisen DJ, van der Wal MH. Self-reported versus ‘true’ adherence in heart failure patients: a study using the medication event monitoring system. Neth Heart J. 2012;20(7–8):313–319. PubMed PMC

Patterns of Non-adherence to Supplementation with Calcium and Vitamin D in Persistent Postmenopausal Women Are Similar at Start and 1 Year Later: A Qualitative Longitudinal Study